Limits...
Immunohistochemical analysis of RTKs expression identified HER3 as a prognostic indicator of gastric cancer.

Ema A, Yamashita K, Ushiku H, Kojo K, Minatani N, Kikuchi M, Mieno H, Moriya H, Hosoda K, Katada N, Kikuchi S, Watanabe M - Cancer Sci. (2014)

Bottom Line: Analysis using a multivariate proportional hazard model identified the most significant RTKs that represented independent prognostic relevance.Significant prognostic relevance was similarly confirmed for IGF-1R (P = 0.014), and EGFR (P = 0.030), but not for EphA2 or HER2 expression.Of the 53 patients who recurred, 40 patients (75.5%) were HER3-positive.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Kitasato University School of Medicine, Kitasato 1-15-1, Minami-ku, Sagamihara, Kanagawa, 252-0374, Japan.

Show MeSH

Related in: MedlinePlus

The 5y-RFS of patients with combination both EGFR and HER3 expression, as detected using IHC, was analyzed using Kaplan Meier survival curves. (a) The 5y-RFS of combination both EGFR and HER3 overexpression was 44.4%, and indicated poor prognosis (P = 0.0003). (b) The 5y-RFS of combination both EGFR and HER3 overexpression was 74.3% in pStage II. (c) The 5y-RFS of combination both EGFR and HER3 overexpression was 34.5% and indicated poor prognosis comparing other combinations in pStage IIIA. (d) The 5y-RFS of combination both EGFR and HER3 overexpression was 25.0% and indicated poor prognosis comparing other combinations in pStage IIIB.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317956&req=5

fig06: The 5y-RFS of patients with combination both EGFR and HER3 expression, as detected using IHC, was analyzed using Kaplan Meier survival curves. (a) The 5y-RFS of combination both EGFR and HER3 overexpression was 44.4%, and indicated poor prognosis (P = 0.0003). (b) The 5y-RFS of combination both EGFR and HER3 overexpression was 74.3% in pStage II. (c) The 5y-RFS of combination both EGFR and HER3 overexpression was 34.5% and indicated poor prognosis comparing other combinations in pStage IIIA. (d) The 5y-RFS of combination both EGFR and HER3 overexpression was 25.0% and indicated poor prognosis comparing other combinations in pStage IIIB.

Mentions: EGFR was not significant, but marginally significant independent prognostic factor instead of HER3 (Table 2). Combination of both EGFR and HER3 was significant poor prognostic factor in all the gastric cancer cases (n = 167) (Fig. 6a). Interestingly, 5-year RFS was excellent in stage II cases other than combination of both EGFR IHC 2+/3+ and HER3 1+/2+ (Fig. 6b). On the other hand, 5-years RFS was dismal in stage IIIA (34.5%) and stage IIIB (25.0%) in cases with combination of both EGFR IHC 2+/3+ and HER3 1+/2+ (Fig. 6c, and 6d).


Immunohistochemical analysis of RTKs expression identified HER3 as a prognostic indicator of gastric cancer.

Ema A, Yamashita K, Ushiku H, Kojo K, Minatani N, Kikuchi M, Mieno H, Moriya H, Hosoda K, Katada N, Kikuchi S, Watanabe M - Cancer Sci. (2014)

The 5y-RFS of patients with combination both EGFR and HER3 expression, as detected using IHC, was analyzed using Kaplan Meier survival curves. (a) The 5y-RFS of combination both EGFR and HER3 overexpression was 44.4%, and indicated poor prognosis (P = 0.0003). (b) The 5y-RFS of combination both EGFR and HER3 overexpression was 74.3% in pStage II. (c) The 5y-RFS of combination both EGFR and HER3 overexpression was 34.5% and indicated poor prognosis comparing other combinations in pStage IIIA. (d) The 5y-RFS of combination both EGFR and HER3 overexpression was 25.0% and indicated poor prognosis comparing other combinations in pStage IIIB.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317956&req=5

fig06: The 5y-RFS of patients with combination both EGFR and HER3 expression, as detected using IHC, was analyzed using Kaplan Meier survival curves. (a) The 5y-RFS of combination both EGFR and HER3 overexpression was 44.4%, and indicated poor prognosis (P = 0.0003). (b) The 5y-RFS of combination both EGFR and HER3 overexpression was 74.3% in pStage II. (c) The 5y-RFS of combination both EGFR and HER3 overexpression was 34.5% and indicated poor prognosis comparing other combinations in pStage IIIA. (d) The 5y-RFS of combination both EGFR and HER3 overexpression was 25.0% and indicated poor prognosis comparing other combinations in pStage IIIB.
Mentions: EGFR was not significant, but marginally significant independent prognostic factor instead of HER3 (Table 2). Combination of both EGFR and HER3 was significant poor prognostic factor in all the gastric cancer cases (n = 167) (Fig. 6a). Interestingly, 5-year RFS was excellent in stage II cases other than combination of both EGFR IHC 2+/3+ and HER3 1+/2+ (Fig. 6b). On the other hand, 5-years RFS was dismal in stage IIIA (34.5%) and stage IIIB (25.0%) in cases with combination of both EGFR IHC 2+/3+ and HER3 1+/2+ (Fig. 6c, and 6d).

Bottom Line: Analysis using a multivariate proportional hazard model identified the most significant RTKs that represented independent prognostic relevance.Significant prognostic relevance was similarly confirmed for IGF-1R (P = 0.014), and EGFR (P = 0.030), but not for EphA2 or HER2 expression.Of the 53 patients who recurred, 40 patients (75.5%) were HER3-positive.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Kitasato University School of Medicine, Kitasato 1-15-1, Minami-ku, Sagamihara, Kanagawa, 252-0374, Japan.

Show MeSH
Related in: MedlinePlus